Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.36 |
| ▸ | CTSS | P25774 | 6/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 3/20 | 0.35 |
| ▸ | CTSB | P07858 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL6402119 | 1.00 | CTSK (0.36) | CTSKCTSSCYP2D6CTSLCTSB | |
| SCHEMBL5364063 | 0.81 | MGAM (0.37) | — | |
| SCHEMBL5364066 | 0.81 | MGAM (0.37) | — | |
| SCHEMBL15698708 | 0.77 | MGAM (0.47) | — | |
| SCHEMBL4145834 | 0.73 | GRIK1 (0.32) | — | |
| SCHEMBL4145829 | 0.73 | GRIK1 (0.32) | — | |
| SCHEMBL13851870 | 0.73 | GRIK1 (0.32) | — | |
| SCHEMBL14349108 | 0.71 | GRIK1 (0.43) | CTSKCTSSCYP2D6CTSLCTSB | |
| Potassium Ion SCHEMBL6395315 | 0.70 | CA4 (0.33) | CA1CA2 | |
| Potassium Ion SCHEMBL6395320 | 0.70 | CA4 (0.33) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6891059-B2 | Asymmetric synthesis of pregabalin | WARNER-LAMBERT COMPANY (US) | 2005-05-10 | — | — | US | disclosed |
| EP-1250311-B1 | ASYMMETRIC SYNTHESIS OF PREGABALIN | WARNER LAMBERT CO (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20030212290-A1 | Asymmetric synthesis of pregabalin | BURK MARK JOSEPH (US) | 2003-11-13 | — | — | US | disclosed |
| EP-1250311-A1 | ASYMMETRIC SYNTHESIS OF PREGABALIN | WARNER-LAMBERT COMPANY (US) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001055090-A1 | ASYMMETRIC SYNTHESIS OF PREGABALIN | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212290-A1 | Asymmetric synthesis of pregabalin | GABRA5, GABRA6, GABRE | CTSK 4382/4885CTSS 4046/4885CYP2D6 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.